Global pharmaceutical giant Eli Lilly (LLY, Financial) has filed lawsuits against four compound pharmacies, accusing them of illegally producing and selling unapproved compounded drugs containing tirzepatide. These drugs are created by mixing, combining, or altering pharmaceutical ingredients. This legal action follows a recent U.S. court ruling that prohibits pharmacies from replicating its weight loss and diabetes medications.
The four companies targeted in the lawsuit are Mochi Health Corp, Fella Health and Delilah, Willow Health Services, and Henry Meds. Eli Lilly filed the lawsuit in a California court, alleging that these companies are selling unauthorized versions of tirzepatide with additives or oral formulations without providing clinical evidence of safety and efficacy. Tirzepatide is the key active ingredient in Eli Lilly's blockbuster weight loss drug, Mounjaro.
According to the FDA, compound pharmacies were allowed to replicate certain drugs during periods of shortage. However, the FDA recently removed tirzepatide from the shortage list, closing this legal loophole. Eli Lilly has stated its commitment to continue using legal measures to protect its intellectual property.
